Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Mons – page 46

640 clinical trials in Mons, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Mons at a glance
640
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

640 trials in Mons

Open in trial search

Study of Pembrolizumab for Patients with Early Stage Non-Small Cell Lung Cancer After Surgery and Standard Therapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing Teclistamab with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma After 1-3 Prior Treatments

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Study of Lurbinectedin and Atezolizumab for Maintenance Therapy in Patients with Extensive-Stage Small-Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Plasma cell myeloma

Not recruiting

Study of Teclistamab and Lenalidomide as Maintenance Treatment for Newly Diagnosed Multiple Myeloma Patients After Stem Cell Transplantation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Study of ibrutinib and venetoclax combination therapy for patients with relapsed or refractory chronic lymphocytic leukemia who have adequate kidney function

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study of Lurbinectedin Alone or with Irinotecan for Patients with Relapsed Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Irinotecan
  • Sponsor:Pharma Mar S.A.

Hypercholesterolaemia

Not recruiting

Study on Inclisiran and Rosuvastatin for Lowering Cholesterol in Patients with High Cholesterol Levels

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Prostate cancer

Not recruiting

Study on Stereotactic Body Radiation Therapy with or without Durvalumab for Patients with Oligometastatic Hormone-Sensitive Prostate Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Institut De Cancerologie De L Ouest

Study of Atezolizumab and Tiragolumab Compared to Durvalumab for Patients with Advanced Non-Small Cell Lung Cancer After Chemoradiation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with High-Risk HER2-Positive Breast Cancer with Residual Disease After Initial Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Breast cancer

Not recruiting

Study on Alpelisib and Fulvestrant for Men and Postmenopausal Women with Advanced HR-positive, HER2-negative Breast Cancer with PIK3CA Mutation

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Study Comparing Adagrasib and Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Mons

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on lung cancer treatments, including studies of combination therapies with BNT327 and investigations into both small cell and non-small cell variants. Additional research covers breast cancer and cervical cancer treatments.

  • Non-small cell lung cancer therapy optimization
  • Advanced solid tumors treatment
  • Lymphoma treatment innovations

Studies aim to improve survival rates and treatment effectiveness through targeted therapies and immunotherapy combinations.

02 Cardiovascular Studies

Comprehensive research into coronary artery disease and post-stroke treatments, evaluating new antiplatelet therapies and innovative stent technologies. Studies focus on reducing cardiovascular events and improving patient outcomes.

  • Acute coronary syndrome management
  • Stroke prevention strategies
  • Antiplatelet therapy optimization

Investigations aim to enhance treatment protocols and reduce cardiovascular complications.

03 Autoimmune Conditions

Groundbreaking research in multiple sclerosis and psoriatic arthritis treatments, evaluating novel therapeutic approaches including BTK inhibitors and biological treatments.

  • Progressive MS treatment development
  • Arthritis management innovations
  • Long-term therapy effectiveness

Focus on improving quality of life and disease management for patients with chronic autoimmune conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.